In many cases, nerve signals travel from the skin through the spine to the brain driving the itch sensation. NK1 receptors play a major role in transmitting these signals to the brain. The NK1 receptor inhibitor, serlopitant, interrupts the signal transmission from multiple itch triggers to reduce the itch sensation. Menlo Therapeutics has identified several medical conditions where severe itch degrades the quality of life for patients. Itch associated with these conditions is often non-responsive to the current standard of care, including anti-histamines, steroids and drugs with harmful side effects.
Client Overview and description of three indications.
Category Overview and description
Date 29 January 2017